[Clinical and epidemiological features in Neuromyelitis Optica Spectrum Disorder].
Fiche publication
Date publication
juillet 2020
Journal
Journal francais d'ophtalmologie
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Osswald D, De Seze J, Collongues N, Speeg-Schatz C
Lien Pubmed
Résumé
Neuromyelitis optica spectrum disorder (NMO-SD) has been recognized for the past decade. Biomarkers such as anti-Aquaporin 4 antibodies (AQP4) and anti-Myelin Oligodendrocyte Glycoprotein (MOG) have been able to classify NMO-SD into several groups.
Mots clés
Anti-Myelin Oligodendrocyte Glycoprotein (MOG) antibodies, Anti-aquaporin 4 (AQP4) antibodies, Anticorps anti-Myelin Oligodendrocyte Glycoprotein (MOG), Anticorps anti-aquaporines 4 (AQP4), NMO-SD, Neuro-ophtalmologie, Neuro-ophthalmology, Neuromyelitis optica, Neuromyélite optique
Référence
J Fr Ophtalmol. 2020 Jul 3;: